{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-176795","form_type":"8-K","ticker":"MCRB","cik":"0001609809","company_name":"Seres Therapeutics, Inc.","filed_at":"2023-06-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.657982+00:00","generated_at":"2026-06-13T15:32:20.194678+00:00","sec_items":["5.03","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"medium","headline":"Seres increases authorized shares to 240M and updates on Oaktree credit facility tranche conditions","bullets":["Stockholders approved increase in authorized common shares from 200M to 240M; Certificate of Amendment filed June 27, 2023.","Company posted updated corporate presentation disclosing funding conditions for Tranche B and Tranche C of Oaktree Credit Facility.","Management states funding requirements for Tranche B and Tranche C are achievable."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-176795","json":"https://secwatch.observer/filing/0001193125-23-176795.json","markdown":"https://secwatch.observer/filing/0001193125-23-176795.md","text":"https://secwatch.observer/filing/0001193125-23-176795.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1609809/000119312523176795/0001193125-23-176795-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1609809/000119312523176795/d506361d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T15:32:20.194678+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}